Literature DB >> 17473965

Inherited thrombophilia: key points for genetic counseling.

Elizabeth Varga1.   

Abstract

With the evolution of medical genetics to focus on highly prevalent, multifactorial conditions, it is inevitable that genetic counselors will be called upon to participate in the evaluation and counseling of individuals with inherited thrombophilia. The purpose of this review is to educate the genetic counselor on key issues related to risk assessment and genetic counseling for hereditary thrombophilia. The information contained in this document is derived from an extensive review of the literature, as well as the author's personal expertise. Upon completion of this review, the genetic counselor will be able to: a) describe inherited and acquired risk factors for thrombosis, b) collect and interpret personal and family histories to assess risk related to hereditary thrombophilia, c) discuss the potential advantages and disadvantages of thrombophilia testing, including psychosocial aspects and implications for medical management, and d) identify educational and support resources for patients and families.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17473965     DOI: 10.1007/s10897-006-9069-9

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.717


  111 in total

1.  ACOG Practice Bulletin #68: Antiphospholipid syndrome.

Authors: 
Journal:  Obstet Gynecol       Date:  2005-11       Impact factor: 7.661

2.  Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening.

Authors:  P M Ridker; J P Miletich; C H Hennekens; J E Buring
Journal:  JAMA       Date:  1997 Apr 23-30       Impact factor: 56.272

3.  Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis.

Authors:  Olivia Wu; Lindsay Robertson; Sara Twaddle; Gordon Lowe; Peter Clark; Isobel Walker; Ivan Brenkel; Mike Greaves; Peter Langhorne; Lesley Regan; Ian Greer
Journal:  Br J Haematol       Date:  2005-10       Impact factor: 6.998

Review 4.  College of American Pathologists Consensus Conference XXXVI: Diagnostic Issues in Thrombophilia.

Authors: 
Journal:  Arch Pathol Lab Med       Date:  2002-11       Impact factor: 5.534

Review 5.  Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders.

Authors:  Richard D Press; Kenneth A Bauer; Jody L Kujovich; John A Heit
Journal:  Arch Pathol Lab Med       Date:  2002-11       Impact factor: 5.534

6.  Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group.

Authors:  P Brill-Edwards; J S Ginsberg; M Gent; J Hirsh; R Burrows; C Kearon; W Geerts; M Kovacs; J I Weitz; K S Robinson; R Whittom; G Couture
Journal:  N Engl J Med       Date:  2000-11-16       Impact factor: 91.245

7.  Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis.

Authors:  I Martinelli; E Taioli; P Bucciarelli; S Akhavan; P M Mannucci
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-03       Impact factor: 8.311

8.  The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis.

Authors:  S Middeldorp; C M Henkens; M M Koopman; E C van Pampus; K Hamulyák; J van der Meer; M H Prins; H R Büller
Journal:  Ann Intern Med       Date:  1998-01-01       Impact factor: 25.391

Review 9.  Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Shannon M Bates; Ian A Greer; Jack Hirsh; Jeffrey S Ginsberg
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

10.  Homocysteine lowering and cardiovascular events after acute myocardial infarction.

Authors:  Kaare Harald Bønaa; Inger Njølstad; Per Magne Ueland; Henrik Schirmer; Aage Tverdal; Terje Steigen; Harald Wang; Jan Erik Nordrehaug; Egil Arnesen; Knut Rasmussen
Journal:  N Engl J Med       Date:  2006-03-12       Impact factor: 91.245

View more
  4 in total

1.  Combined presence of coagulation factor XIII V34L and plasminogen activator inhibitor 1 4G/5G gene polymorphisms significantly contribute to recurrent pregnancy loss in Serbian population.

Authors:  Ivana Joksic; Zeljko Mikovic; Dejan Filimonovic; Jelena Munjas; Orlic Natasa Karadzov; Amira Egic; Gordana Joksic
Journal:  J Med Biochem       Date:  2020-01-23       Impact factor: 3.402

Review 2.  Genetic counseling for inherited thrombophilias.

Authors:  Elizabeth A Varga
Journal:  J Thromb Thrombolysis       Date:  2007-10-19       Impact factor: 2.300

3.  A semiquantitative metric for evaluating clinical actionability of incidental or secondary findings from genome-scale sequencing.

Authors:  Jonathan S Berg; Ann Katherine M Foreman; Julianne M O'Daniel; Jessica K Booker; Lacey Boshe; Timothy Carey; Kristy R Crooks; Brian C Jensen; Eric T Juengst; Kristy Lee; Daniel K Nelson; Bradford C Powell; Cynthia M Powell; Myra I Roche; Cecile Skrzynia; Natasha T Strande; Karen E Weck; Kirk C Wilhelmsen; James P Evans
Journal:  Genet Med       Date:  2015-08-13       Impact factor: 8.822

4.  COVID-19 Vaccine and Death: Causality Algorithm According to the WHO Eligibility Diagnosis.

Authors:  Cristoforo Pomara; Francesco Sessa; Marcello Ciaccio; Francesco Dieli; Massimiliano Esposito; Giovanni Maurizio Giammanco; Sebastiano Fabio Garozzo; Antonino Giarratano; Daniele Prati; Francesca Rappa; Monica Salerno; Claudio Tripodo; Pier Mannuccio Mannucci; Paolo Zamboni
Journal:  Diagnostics (Basel)       Date:  2021-05-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.